°òª÷·|»PÂø»x | §ÜÀù¸ê°T | ·|­ûµù¥U | ¯f¤Í¶é¦a | ÂåÀøÅU°Ý | ³Ì·s¤åÄm | ¬ÛÃöºô¯¸ | ½u¤W®½´Ú | ³Ì·s®ø®§


Âಾ©Ê¨ÅÀù¨Ï¥ÎTrastuzumab¬°¥DªºªvÀø­p¹º®É
¦å²MHer-2/neuºÊ±±¥i¥H¹w´úªvÀø¤ÏÀ³¤ÎµL¯e¯f¦s¬¡´Á

Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer
Clin Cancer Reser, 2004, Vol.10:1618-24
By Wolfgang J. Kostler, Barbara Schwab, et. al

ĶªÌ¡G¾H¥ò¤¯

¤@¡B ¬ã¨s­I´º
¥»¬ã¨sªº¥Øªº¦b±´°Q¡A¿©±wÂಾ©Ê¨ÅÀùªº¯f±w¨Ï¥Îtrastuzumab¬°¥DªºªvÀø­p¹º®É¡A¯f¤H¦å²MªºHer-2/neu²Ó­M¥~¤ù¬q(extracellular domain, ECD)¿@«×ªº¦­´ÁÅܤơA¬O§_¯à°÷¹w´ú¯f¤HªºÁ{§É¯e¯f¶i®i¡C

¤G¡B ¬ã¨s¹ï¶H
¦³55¦ì¿©±wÂಾ©Ê¨ÅÀùªº¯f±w¡A¦o­Ì§¡¦³Her-2/neuªº¹L«×ªí²{(Her-2/neu-overexpressing)¡C¦b¨C¶gµ¹¤©trastuzumabªvÀø«e¡A¥ý¦¬¶°¦o­Ìªº¦å²M¡A¨Ã¨Ï¥ÎELISA¤èªk´ú©wHer-2/neu¿@«×¡C¦b³sÄòªºªvÀø´Á¶¡°µ¿@«×ªººÊ±±¡Aµû¦ô³sÄò©ÊºÊ±±¬O§_¯à°µ¬°¯e¯f¶i®iªº«ü¼Ð¡C

¤T¡B ¬ã¨sµ²ªG
­Y¯f±w¦bªvÀø«eªºHer-2/neu²Ó­M¥~¤ù¬q(ECD)¿@«×¸û°ª¡]„d 15 ng/mL¡^¡A«h¨äªvÀø¤ÏÀ³²v¦³©úÅã¸û°ª¡]35% vs. 7%¡Ap­È¡×0.045¡^¡F¦ý¡uµL¯e¯f¶i®i¦s¬¡´Á(progression-free survival)¡v¤Î¡uÁ`¦s¬¡´Á(overall survival)¡v¦bHer-2/neu²Ó­M¥~¤ù¬q(ECD)¿@«×¥¿±`¤Î¸û°ªªº¯f±w¤§¶¡¡A«hµL©úÅã®t²§¡C
­Y¯f±w¹ïªvÀø¦³¤ÏÀ³¡AHer-2/neu²Ó­M¥~¤ù¬q(ECD)¿@«×¦bªvÀø°_©lªº²Ä8¤Ñ¡A´N·|¦³·N¸q¦a¤U­°¡]¨C¶g´ú±oªº¿@«×»Pbaseline¬Û¤ñ¸û¡A©Ò¦³ªºp­È§¡¡Õ0.001¡^¡C¬Û¹ï¦a¡A¦b¯e¯f¤´¶i®iªº¯f±w¤¤¡A¨äHer-2/neu²Ó­M¥~¤ù¬q(ECD)¿@«×«h¨S¦³©úÅã§ïÅÜ¡C
¦hÅܼÆÅÞ¿è°jÂk¤ÀªR(multiple logistic regression analyses)Åã¥Ü¡A¦b¨Ï¥Îtrastuzumab¬°¥DªºªvÀø­p¹º®É¡A¦bªvÀø²Ä8¤Ñ¥H«á¡AHer-2/neu²Ó­M¥~¤ù¬q(ECD)¿@«×´î¤Öªº¡u°ÊºAÅܤÆ(kinetics)¡v¥i¥Î©ó·Ç½T¹w´úªvÀø¤ÏÀ³²vªº°ß¤@¦]¤l¡]p­È¡×0.020¡^¡C¦¹¥~¡AHer-2/neu²Ó­M¥~¤ù¬q(ECD)¿@«×¼W¥[ªº³sÄò©Ê©w¶q¡A¥i¦bªvÀøªº²Ä15¤Ñ®É§Y¥i¹w´ú¯e¯f®iªºrisk¡]p­È¡×0.010¡^¡C

¥|¡B µ²½×
Her-2/neu²Ó­M¥~¤ù¬q(ECD)¿@«×ªº³sÄò©ÊºÊ´ú(serial monitoring)À³¥i°µ¬°¤@¶µ¦³¥Îªº¤u¨ã¡AÀ³¥Î¦b¨Ï¥Îtrastuzumab¬°¥DªºªvÀø­p¹º®É¡A¥i¥Î¨Ó¦­´Á¹w´úªvÀø¤ÏÀ³¡BµL¯e¯f¶i®i¦s¬¡´Á(progression-free survival)¡A¦Ó§ó¯à±NªvÀø¤è¦¡»P¸ê·½°µ¾A·íªº¦w±Æ¡C

 
 
µn¿ý®É¶¡¡G93¦~8¤ë27¤é